(TheNewswire)

Kelowna, British Columbia – May 16,2025 – TheNewswire –Rize Oncology Inc. RIZE (“Rize
Oncology” or the “Company”), a clinical-stage pharmaceutical
company focused on developing innovative oncology therapeutics, today
announced several strategic developments to support the ongoing
advancement of its drug candidate, STS-201.

The Company has received the approval of a simplemajority of its disinterested shareholders, as well as the approval ofthe of the Canadian Securities Exchange (“CSE”), to voluntarilydelist its common shares from the CSE.  It is expected that thedelisting will become effective at the close of trading on May 23,2025. Notwithstanding the delisting, Rize Oncology will continue to bea reporting issuer in each of the provinces of British Columbia,Alberta and Ontario and will continue to make all required publicfilings on the System for Electronic Document Analysis and Retrieval(SEDAR+) in accordance with applicable Canadian securitieslaws.

“We believethe current market conditions and trading activity on the CSE do notreflect the underlying value or long-term potential of STS-201 or RizeOncology as a whole,” said Daren Graham, Executive Chairpersonof Rize Oncology. “With this transition, we believe we will havegreater flexibility to execute our clinical developmentstrategy.”

Advancing STS-201 and Expanding Globally

As part of its operational strategy, Rize Oncology
recently established a wholly-owned subsidiary in Australia. In
addition to serving as a regional hub for R&D and clinical
activities, the establishment of Rize Oncology Australia Pty Ltd will
position the Company to access Australia’s 43.5% R&D rebate
program and related grant opportunities.

“Establishing a presence in Australia reflects our commitment to
building the company in a capital-efficient and strategically focused
way,” stated William Garner, MD, co-founder and director of Rize
Oncology. “Rize is just the latest EGB Ventures
portfolio company to expand into the region. In addition to EGB’s
large and growing network of professionals and investors in the
country, we intend to take full advantage Australia’s supportive
regulatory environment, world-class clinical infrastructure, and
meaningful financial incentives for R&D-stage pharma
companies.”

CDMO
Agreement with PharmSky Research

Rize Oncology has also entered into a manufacturing
agreement with PharmSky Research Pty Ltd, a Melbourne-based contract
development and manufacturing organization (CDMO) and initiated
manufacturing of the drug product and clinical trial materials
required for the Company’s first clinical trial of STS-201, a novel
small-molecule therapy in development for soft tissue sarcoma (STS).
Based on the significant amount of clinical data available for the
active molecule in STS-201, Rize Oncology believes STS-201 holds
significant potential as an anti-metastatic compound and as a
neoadjuvant to radiation therapy in STS and other solid tumors.

Looking Ahead

“These steps
mark a significant inflection point for the company,” said Mr.
Graham. “We are laser-focused on bringing STS-201 into the clinic,
and these operational enhancements align our structure with that
goal.”

About Rize Oncology Inc.

Rize Oncology Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of STS-201, a
small-molecule drug with a unique mechanism of action, currently being
evaluated for its potential in treating soft tissue sarcoma and other
cancers.​

Contact:

Roland Boivin, CEO

(833) 294-4363 ext. 1

roland@rizeoncology.com

Daren Graham, Executive Chairman

(833) 294-4363 ext. 2

daren@rizeoncology.com

Forward-Looking Statements

This news release contains statements that constitute
“forward-looking statements.” Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause Rize Oncology’s actual results, performance or
achievements, or developments in the industry to differ materially
from the anticipated results, performance or achievements expressed or
implied by such forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but
not always, identified by the words “expects,” “plans,”
“anticipates,” “believes,” “intends,” “estimates,”
“projects,” “potential” and similar expressions, or that
events or conditions “will,” “would,” “may,” “could”
or “should” occur. Forward-looking statements in this document
include the Company’s expectation that its common shares will be
delisted from the CSE and the effective date thereof, the expectation
that the delisting will provide greater flexibility for Rize Oncology
to execute on its clinical development strategy, its expectation that
STS-201 holds significant potential as an anti-metastatic compound and
as a neoadjuvant to radiation therapy in STS and other solid tumors,
and all other statements that are not statements of historical
fact.

Although Rize Oncology believes the forward-looking
information contained in this news release is reasonable based on
information available on the date hereof, by their nature
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements, or other future events, to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements.  By their
nature, these statements involve a variety of assumptions, known and
unknown risks and uncertainties and other factors, which may cause
actual results, levels of activity and achievements to differ
materially from those expressed or implied by such statements.

Examples of such assumptions, risks and uncertainties
include, without limitation, assumptions, risks and uncertainties
associated with general economic conditions; adverse industry events;
future legislative and regulatory developments; the Company’s
ability to access sufficient capital from internal and external
sources, and/or inability to access sufficient capital on favorable
terms; the ability of Rize Oncology to implement its business
strategies; competition; the ability of Rize to obtain and retain all
applicable regulatory and other approvals and other assumptions, risks
and uncertainties that may be disclosed in the Company’s continuous
disclosure record from time to time.

Copyright (c) 2025 TheNewswire – All rights reserved.